Lifecore Biomedical, Inc. (LFCR) vs Sofgen Pharma S.A (PROCF)

Lifecore Biomedical, Inc. and Sofgen Pharma S.A are both Drug Manufacturers Specialty & Generic companies. Lifecore Biomedical, Inc. is the larger, with a market value of $162.4M against $114.0M — 1.4× the size. Sofgen Pharma S.A grew revenue faster over the last twelve months: 5.10% against −10.0%. Sofgen Pharma S.A has the higher net margin (9.52% vs −37.5%) and the higher return on invested capital (15.2% vs −2.80%). Across the 16 metrics below, Sofgen Pharma S.A leads on 13 and Lifecore Biomedical, Inc. on 3.

Valuation

Metric LFCR PROCF Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 1.32 n/m 2.25
P/B n/m n/m 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m 3.29 12.29
EV/Sales 2.73 0.70 2.56
Earnings yield (23.10%) 0.00% (2.99%)
Free cash flow yield (3.21%) 0.00% 0.00%

Profitability

Metric LFCR PROCF Drug Manufacturers Specialty & Generic median
Gross margin 26.86% 56.16% 53.94%
Operating margin (6.89%) 17.01% 0.00%
Net margin (37.54%) 9.52% 0.00%
Free cash flow margin (4.24%) 17.66% 0.00%
Return on equity 201.15% (213.06%) (0.40%)
Return on assets (19.32%) 8.82% (3.32%)
Return on invested capital (2.80%) 15.21% 0.00%

Growth

Metric LFCR PROCF Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (10.03%) 5.10% 10.01%
EPS growth (last fiscal year) (439.33%) (270.30%) —
Revenue growth, 5-year CAGR (4.24%) (1.82%) 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LFCR PROCF Drug Manufacturers Specialty & Generic median
Debt to equity 11.50 (435.78) 0.05
Current ratio 3.87 0.64 2.31
Net debt to EBITDA (15.59) (7.21) 0.85

Dividend

Metric LFCR PROCF Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric LFCR PROCF Drug Manufacturers Specialty & Generic median
Market cap 162.39m 113.95m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack